Lilly's Heart Study Sets Up Showdown With Novo's Victoza
- Victoza cardiovascular data expected as early as first quarter
- Novo sees little impact from Lilly given Victoza's efficacy
This article is for subscribers only.
Unprecedented results from a cardiovascular study on a diabetes medicine sold by Eli Lilly & Co. and Boehringer Ingelheim GmbH sets up a showdown with rival Novo Nordisk A/S, which will release data from a similar study on its competing drug next year.
Lilly and Boehringer’s medicine, called Jardiance, reduced the risk of heart attacks, strokes and cardiovascular deaths by 14 percent in a study of more than 7,000 people with adult-onset diabetes and a high risk of heart problems. No other diabetes drug has shown such a benefit, which has sent a “seismic shock” through the diabetes market, Bloomberg Intelligence said.